Orthokeratology (ortho-K) is one of the most discussed myopia control options — it provides daytime freedom from glasses or contact lenses while potentially slowing axial elongation. But ortho-K has practical correction ranges, and beyond those ranges the approach changes substantially.
If you have high myopia (−6D and above), understanding exactly where the evidence-based correction ceiling sits, what happens beyond it, and how this affects both vision and myopia control claims is essential before investing time and money in the treatment.
The most widely studied standard range for orthokeratology is approximately −6.00D of myopia with up to −1.50D of corneal astigmatism. This reflects both the inclusion criteria used in the majority of RCTs and meta-analyses, and the range covered by most regulatory approvals for established lens designs — though specific approved ranges vary by design and jurisdiction.
The 2021 systematic review and meta-analysis by Tan et al. (which included 45 papers) defined its eligible population as myopes from −0.75 to −6.00D — consistent with where robust evidence exists. The Contact Lens Update clinical review (Bartlett, 2019) states the same −6.00D with −1.50D astigmatism boundary as the currently accepted standard range.
Ortho-K reshapes the cornea by gently flattening its central surface overnight using a specially designed rigid gas-permeable lens. The midperipheral cornea is simultaneously steepened. This creates a "treatment zone" that corrects the central refractive error, and a peripheral defocus pattern thought to slow axial elongation.
The ceiling exists because there are physical limits to how much a cornea can safely be reshaped:
Beyond the standard −6.00D ceiling, ortho-K is not simply "unavailable" — but the approach and the expectations change fundamentally.
Some ortho-K practitioners fit lenses beyond −6.00D using a partial-correction strategy: the ortho-K lens corrects a portion of the myopia (e.g., −4.00D out of a −7.00D total), with the residual −3.00D corrected by daytime glasses or soft contact lenses.
A key paper by Charm & Cho examined this approach in children with myopia beyond the standard range. They found that the myopia control efficacy — measured by axial elongation — was comparable to full-correction ortho-K in the standard range. In other words, partial correction appears to retain the myopia control benefit even when full daytime uncorrected vision is not achieved.
This is an important distinction: for someone seeking ortho-K primarily for myopia control rather than daytime glasses freedom, partial correction at −7.00D or −8.00D may be a viable option — provided they are willing to wear daytime supplemental correction.
Some manufacturers offer ortho-K lens designs marketed for extended correction ranges beyond −6.00D — occasionally up to −8D or slightly beyond in highly customized fitting scenarios. These should be approached with the following caveats:
For myopia in the −10D to −13D range — such as that discussed in the High Myopia Living article — standard ortho-K is not a realistic option for full daytime correction. Even aggressive partial-correction approaches would leave substantial residual myopia requiring correction.
Within its effective range, ortho-K has reasonable myopia control evidence. The 2021 systematic review (Tan et al.) found:
The IMI 2025 Interventions White Paper (Bullimore et al.) confirms ortho-K as a well-supported myopia control modality with multiple RCT-grade studies, placing it alongside dual-focus soft contact lenses and myopia control spectacle lenses as established treatments.
Ortho-K involves overnight rigid lens wear, which carries a small but real risk of microbial keratitis — a potentially sight-threatening corneal infection. The systematic review (Tan et al.) notes that approximately 20% of children discontinue ortho-K lenses, primarily due to fitting issues such as insufficient correction or poor lens centration.
Reported microbial keratitis incidence in ortho-K wearers appears low in most published series, but exact comparative risk estimates vary across studies and populations — the literature does not support a single definitive comparative figure. The 2021 systematic review acknowledges that total subject-time exposure in RCT conditions remains limited, and long-term large-scale safety data continue to accumulate.
At higher prescription ranges (beyond −6D), the risks associated with inadequate lens centration and optical irregularity are greater — another reason why practitioner experience matters more as prescription increases.
| Prescription Range | Ortho-K Status | Daytime Vision Goal | Myopia Control Evidence |
|---|---|---|---|
| −1.00D to −6.00D (with ≤−1.50D astigmatism) | Standard range; widely available | Full daytime uncorrected vision typically achievable | Well-supported; ~45% efficacy vs single-vision controls (meta-analyses) |
| −6.00D to −8.00D | Beyond standard range; specialist fitting required | Partial correction; daytime supplemental correction likely needed | Limited but Charm & Cho data suggest comparable control efficacy with partial correction |
| −8.00D to −10.00D | Extended-range or partial correction only; very limited evidence | Substantial residual correction needed; freedom from glasses unlikely | Insufficient independent evidence to make reliable claims |
| >−10.00D (high myopia) | Not a realistic correction option; not standard practice | Not achievable | Not applicable at this range; other modalities warranted |
If you have high myopia and are considering ortho-K for myopia control specifically, the conversation with a specialist should include:
For people with stable high myopia seeking daytime spectacle freedom, implantable collamer lenses (ICL) are often considered the more appropriate option above −8D, as they provide full refractive correction through a surgical approach rather than relying on corneal reshaping within its practical limits.